-
Mashup Score: 13Infections following bispecific antibody therapy in MM: incidence and characteristics - 25 day(s) ago
Here, we summarize a multicenter, retrospective study conducted in France on the incidence and characteristics of infections following treatment with bispecific antibody therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty phenotype (PRFP) and the International Myeloma Working Group Frailty Index (IMWG FI).
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5FDA approves idecabtagene vicleucel for triple-class-exposed RRMM - 1 month(s) ago
On April 5, 2024, the U.S. FDA granted approval to idecabtagene vicleucel for the treatment of triple-class-exposed relapsed/refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, proteasome inhibitor, and an anti-CD38 antibody.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2CAR T-cell therapy in older patients: Efficacy and rates of immune-mediated toxicity - 1 month(s) ago
We summarize a systematic review and meta-analysis by Akhtar et al. investigating the efficacy of CAR T-cell therapy and rates of immune-mediated toxicity in patients ≥65 years old with multiple myeloma.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4 - 1 month(s) ago
Here we summarize the rationale and latest clinical trial data investigating the use of cilta-cel in earlier lines of therapy in multiple myeloma.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
Could cilta-cel be successfully implemented into earlier lines of therapy in #MultipleMyeloma? Read more here for the rationale for incorporating cilta-cel in lines 1–3 and the latest data from CARTITUDE-2 and CARTITUDE-4 👉 https://t.co/ffp4UYCGH2 #mmsm #myeloma #CAR-T #RRMM https://t.co/cRYFbDwhGH
-
-
Mashup Score: 1What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma? - 1 month(s) ago
During the EHA-EBMT 6th European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Paola Neri, University of Calgary, Calgary, CA. We asked, What factors contribute to resistance to BCMA-targeted CAR T-cell therapies in multiple myeloma?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Factors associated with unsustained MRD-negativity in patients with MM eligible for transplant - 2 month(s) ago
Here, we summarize a report published by Guerrero et al. in Blood on predictors of unsustainable MRD-negativity in patients with multiple myeloma who are eligible for transplant.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Dermatological toxicities associated with talquetamab in RRMM - 2 month(s) ago
Here, we summarize a retrospective study published by Lery et al. in Journal of the American Academy of Dermatology on the dermatological toxicities associated with the use of talquetamab for the treatment of RRMM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5European Commission approves idecabtagene vicleucel for the treatment of triple-class-exposed RRMM - 2 month(s) ago
On March 20, 2024, the European Commission granted approval to ide-cel for the treatment of triple-class-exposed RRMM with two or more prior therapies, including an IMiD, PI, and an anti-CD38 antibody with subsequent disease progression.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
Did you know that 44% of infections after treatment with #bispecific antibodies are in the lower respiratory tract? Our latest article details the incidence and characteristics of infections associated with the use of bsAbs! 👉 https://t.co/Wa3rGGAVFq #mmsm #MultipleMyeloma https://t.co/xhLYUMCXMb